Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.39 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18815238 | 1.00 | OPRD1 (0.40) | OPRD1HCRTR1HCRTR2BAZ2A | |
| SCHEMBL9980544 | 0.86 | HCRTR1 (0.40) | OPRD1HCRTR1HCRTR2 | |
| SCHEMBL1914149 | 0.86 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL17396070 | 0.82 | ALDH1A1 (0.46) | — | |
| SCHEMBL17396071 | 0.82 | ALDH1A1 (0.46) | — | |
| SCHEMBL23247998 | 0.77 | OPRD1 (0.48) | OPRD1HCRTR1HCRTR2 | |
| SCHEMBL16130727 | 0.77 | OPRD1 (0.46) | OPRD1HCRTR1HCRTR2 | |
| SCHEMBL13505317 | 0.77 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL9936981 | 0.77 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL1293417 | 0.77 | HCRTR1 (0.37) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, IMPA1 | OPRD1 4085/4885HCRTR1 3945/4885HCRTR2 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.